COVID-19 trials registries data warehouse

http://www.chictr.org.cn/showproj.aspx?proj=50004

Jian Bo

boj301@sina.com

2020-02-24

Not recruiting

RCT

Randomized

Parallel

Blind label

single-center

Treatment

Subjects who met all of the following conditions entered the trial: 1. Male or female patients aged 16 to 75 years, 2. willing to sign informed consent, 3. Based on the criteria for suspected cases of COVID-19 infection, sputum, throat swabs, lower respiratory tract secretions and other specimens were tested for positive COVID-19 nucleic acid by real-time fluorescent RT-PCR, or viral gene sequencing was performed with known COVID- 19 highly homologous, 4. The imaging findings are consistent with pneumonia.

Subjects who meet one of the following conditions will not be eligible for the trial: 1. pregnant or lactating women, 2. Malignant tumors, patients with other severe systemic diseases and mental illness, 3. Those who have recently participated in other clinical trials, 4. There is evidence of drug addiction within one year before joining the trial, 5. Unable or unwilling to provide informed consent or comply with test requirements, 6. Combined with HIV, tuberculosis, influenza virus, adenovirus and other respiratory infections.

2

Chinese PLA General Hospital

16

75

China

Severe/critical disease at enrollment

7: Severe/critical disease at enrollment

60

Clinical index;

| Declared number of arm (2.0) differs from found arms (3.0)

Phase 2

[{"arm_notes": "", "treatment_id": 787, "treatment_name": "Mesenchymal stem cells", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]